Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?
Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.
You may also be interested in...
After a major setback to its lead asset last year, Faron looks to novel immunotherapy
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.